8-K: Evolus Announces Record Preliminary 2023 Revenue, Exceeds Expectations and Issues Strong 2024 Guidance

Evolus reports preliminary unaudited full-year 2023 revenue of approximately $202 million, exceeding guidance and setting a strong foundation for 2024 growth.

Summary

• Evolus announced preliminary unaudited net revenue of approximately $61 million for the fourth quarter of 2023, representing a 40% increase year-over-year and a 22% increase sequentially.
• Full-year 2023 preliminary unaudited net revenue reached approximately $202 million, a 36% increase compared to 2022, and exceeding the company's guidance of $194 to $198 million.
• The company's 2024 net revenue guidance is set between $255 million and $265 million, projecting a 26% to 31% growth from the preliminary 2023 results.
• Evolus added over 2,900 new accounts in 2023, bringing the total number of accounts purchasing Jeuveau to over 12,400.
• The Evolus Rewards consumer loyalty program grew by 55% in 2023, reaching approximately 750,000 consumers.
• The company's cash and cash equivalents were $62.8 million as of December 31, 2023, compared to $38.7 million on September 30, 2023.
• Evolus expects to achieve positive non-GAAP operating income in 2025 and believes its existing liquidity will fund operations until then.
• The company plans to expand its global footprint in 2024, particularly in Europe, and anticipates submitting Premarket Approval applications for dermal fillers in the U.S. by mid-year 2024.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the strong revenue growth, exceeding expectations, and positive future outlook. The company's expansion plans and progress towards profitability further contribute to the high sentiment.

Positives

• The company's revenue growth significantly exceeded expectations for both the fourth quarter and the full year of 2023.
• Evolus experienced a substantial increase in purchasing accounts and consumer loyalty program enrollment.
• The company's cash position improved significantly, reflecting strong sales growth and cash collections.
• Evolus is on track to achieve profitability in 2025, funded by existing liquidity.
• The expansion into new markets and the introduction of new products are expected to drive future growth.

Negatives

• The preliminary results are unaudited and subject to change upon completion of the full audit.
• The company's non-GAAP operating expenses are expected to increase in 2024 due to the European Filler License agreement.
• The issuance of 610,000 shares for the European distribution rights will be recorded as IPR&D expense of up to $5.9 million.

Risks

• The company's future performance is subject to risks and uncertainties, including the ability to comply with settlement agreements and secure funding.
• Unfavorable global economic conditions could impact consumer spending and the adoption of Evolus products.
• The company faces competition and market dynamics that could affect its ability to launch and commercialize products successfully.
• Regulatory approvals for new products are not guaranteed and could be delayed.
• The company relies on third parties for regulatory approvals and product development.

Future Outlook

Evolus anticipates continued growth in 2024, driven by increased market penetration, expansion into new markets, and the launch of new products. The company expects to achieve positive non-GAAP operating income in 2025 and believes its existing liquidity will fund operations until then.

Management Comments

• We believe the preliminary results of the fourth quarter and full-year 2023 are clear indications of our strong operational execution and significant market share gains.
• We are thrilled to have achieved record results and exceeded our guidance for the year, positioning us to carry this strong momentum and drive growth into 2024.
• In 2023, the Company achieved several significant milestones, including the expansion of our portfolio with the addition of late-stage dermal fillers expected to be launched in the U.S. and Europe in 2025, expanding our estimated total addressable market by 78% to approximately $6 billion.

Industry Context

This announcement reflects a positive trend in the aesthetic neurotoxin market, with Evolus demonstrating strong growth and market share gains. The expansion into dermal fillers positions the company to compete more broadly in the aesthetics market, aligning with the industry's trend towards offering a wider range of products and services.

Comparison to Industry Standards

• Evolus's 36% revenue growth for 2023 is strong compared to the overall aesthetics market, which is growing at a more moderate pace.
• Allergan, a major player in the aesthetics market, has seen growth in the single digits in recent years, making Evolus's growth rate particularly impressive.
• The expansion into dermal fillers is similar to moves by other companies like Galderma and Merz, who offer a range of aesthetic products.
• Evolus's focus on a digital platform and customer loyalty programs is a strategy also employed by other companies in the industry to enhance customer engagement and retention.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and positive outlook.
• Employees may be motivated by the company's success and expansion plans.
• Customers will benefit from the expansion of the product portfolio and the loyalty program.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial position.

Next Steps

• Evolus will release its full audited financial results for the fourth quarter and full-year 2023 in early March 2024.
• The company plans to expand its global footprint by entering additional European countries in 2024.
• Evolus anticipates submitting Premarket Approval applications for dermal fillers with the FDA by mid-year 2024.
• The company expects regulatory approvals for dermal fillers in Europe in the second half of 2024.

Key Dates

Keywords

Evolus, Jeuveau, Nuceiva, dermal fillers, revenue, neurotoxin, aesthetics, financial results, market share, growth, profitability, FDA, Europe